Orion Oyj (OTCMKTS:ORINY) Short Interest Down 92.0% in April

Orion Oyj (OTCMKTS:ORINY - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 400 shares, a drop of 92.0% from the March 31st total of 5,000 shares. Based on an average daily trading volume, of 7,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company's stock are short sold.

Orion Oyj Price Performance

Shares of Orion Oyj stock remained flat at $31.32 on Wednesday. 161 shares of the stock were exchanged, compared to its average volume of 2,733. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25. The stock has a market cap of $8.84 billion, a PE ratio of 24.86 and a beta of 0.15. The firm's 50-day moving average price is $29.06 and its 200 day moving average price is $25.97. Orion Oyj has a 52-week low of $19.97 and a 52-week high of $31.32.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $373.03 million for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. On average, analysts forecast that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Orion Oyj Increases Dividend

The firm also recently declared a dividend, which was paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th were paid a dividend of $0.4478 per share. This is a positive change from Orion Oyj's previous dividend of $0.24. The ex-dividend date of this dividend was Monday, April 7th. Orion Oyj's payout ratio is presently 24.43%.

Analyst Upgrades and Downgrades

Separately, Nordea Equity Research cut Orion Oyj to a "hold" rating in a research note on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.